Study of Pelabresib add-on to Ruxolitinib in Japanese Adult Patients With Myelofibrosis
Abroad (travel likely)RecruitingPHASE1
Conditions
Primary Myelofibrosis (PMF) · Post-polycythemia Vera Myelofibrosis (Post-PV MF) · Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Novartis Investigative Site, Kamogawa, Chiba, Japan
Novartis Investigative Site, Sapporo, Hokkaido, Japan
Novartis Investigative Site, Kamakura, Kanagawa, Japan
Novartis Investigative Site, Kurashiki, Okayama-ken, Japan
Novartis Investigative Site, Bunkyo Ku, Tokyo, Japan
Novartis Investigative Site, Chūō, Yamanashi, Japan
Novartis Investigative Site, Kumamoto, Japan
Study leads
Novartis Pharmaceuticals
Study Director
Novartis Pharmaceuticals